NRIX: financial statements from SEC — TradeAlmanac

NRIX

Nurix Therapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Feb 28, 2026	Aug 31, 2025	May 31, 2025	Feb 28, 2025	Aug 31, 2024	May 31, 2024
Revenue	6m	8m	44m	18m	13m	12m
Research and development	84m	86m	78m	70m	55m	49m
Selling, general and administrative	15m	13m	14m	12m	12m	12m
Operating expenses	99m	99m	92m	81m	67m	61m
Operating income	−92m	−91m	−48m	−63m	−55m	−49m
Pre-tax income	—	−86m	−43m	−56m	−49m	−44m
Income tax	—	0	760,000	0	82,000	90,000
Net income	−87m	−86m	−43m	−56m	−49m	−45m
Earnings per share	−0.79	−1.03	−0.52	−0.67	−0.67	−0.71
Earnings per share, diluted	−0.79	−1.03	−0.52	−0.67	−0.67	−0.71
Weighted average shares	110m	84m	84m	84m	73m	62m
Weighted average shares, diluted	110m	84m	84m	84m	73m	62m

Balance sheet

Metric	Feb 28, 2026	Nov 30, 2025	Aug 31, 2025	May 31, 2025	Feb 28, 2025	Nov 30, 2024	Aug 31, 2024	May 31, 2024
Cash and equivalents	71m	247m	78m	84m	76m	110m	99m	117m
Receivables	—

Cash flow

Metric	Feb 28, 2026	Feb 28, 2025
Operating cash flow	−72m	−61m
Depreciation and amortisation	2m	2m
Share-based compensation	9m	9m
Capital expenditure	1m	3m
Investing cash flow	−124m	26m
Financing cash flow	20m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)